- Home
- CEV vs ENTX Comparison
CEV vs ENTX Comparison
Compare CEV & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- ENTX
- Stock Information
- Founded
- CEV 1999
- ENTX 2010
- Country
- CEV United States
- ENTX Israel
- Employees
- CEV N/A
- ENTX N/A
- Industry
- CEV Finance/Investors Services
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CEV Finance
- ENTX Health Care
- Exchange
- CEV Nasdaq
- ENTX Nasdaq
- Market Cap
- CEV 75.9M
- ENTX 67.2M
- IPO Year
- CEV N/A
- ENTX 2018
- Fundamental
- Price
- CEV $10.40
- ENTX $1.66
- Analyst Decision
- CEV
- ENTX Strong Buy
- Analyst Count
- CEV 0
- ENTX 1
- Target Price
- CEV N/A
- ENTX $10.00
- AVG Volume (30 Days)
- CEV 19.6K
- ENTX 131.0K
- Earning Date
- CEV 01-01-0001
- ENTX 11-08-2024
- Dividend Yield
- CEV 4.23%
- ENTX N/A
- EPS Growth
- CEV N/A
- ENTX N/A
- EPS
- CEV 0.36
- ENTX N/A
- Revenue
- CEV N/A
- ENTX $99,000.00
- Revenue This Year
- CEV N/A
- ENTX N/A
- Revenue Next Year
- CEV N/A
- ENTX N/A
- P/E Ratio
- CEV $29.36
- ENTX N/A
- Revenue Growth
- CEV N/A
- ENTX 607.14
- 52 Week Low
- CEV $8.83
- ENTX $0.52
- 52 Week High
- CEV $10.91
- ENTX $3.35
- Technical
- Relative Strength Index (RSI)
- CEV 39.01
- ENTX 42.82
- Support Level
- CEV $10.36
- ENTX $1.64
- Resistance Level
- CEV $10.44
- ENTX $1.80
- Average True Range (ATR)
- CEV 0.08
- ENTX 0.10
- MACD
- CEV 0.00
- ENTX -0.01
- Stochastic Oscillator
- CEV 18.18
- ENTX 39.54
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.